May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Efficacy of a New Formulation of Timolol 0.5% in Sodium Hyaluronate Vehicle Administered Once Daily
Author Affiliations & Notes
  • S. Giuffrida
    Research Laboratories, Bausch & Lomb Fidia Oftal, Catania, Italy
  • A. Longo
    University of Catania, Institute of Ophthalmology, Catania, Italy
  • V. Amico
    University of Catania, Institute of Ophthalmology, Catania, Italy
  • M.G. Cro
    University of Catania, Institute of Ophthalmology, Catania, Italy
  • M.G. Uva
    University of Catania, Institute of Ophthalmology, Catania, Italy
  • Footnotes
    Commercial Relationships  S. Giuffrida, Bausch&Lomb Fidia Oftal E; A. Longo, None; V. Amico, Bausch&Lomb Fidia Oftal E; M.G. Cro, Bausch&Lomb Fidia Oftal E; M.G. Uva, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 2175. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Giuffrida, A. Longo, V. Amico, M.G. Cro, M.G. Uva; Efficacy of a New Formulation of Timolol 0.5% in Sodium Hyaluronate Vehicle Administered Once Daily . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2175.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: to investigate the efficacy and safety of a new formulation of timolol 0.5% in a mucoadhesive vehicle of sodium hyaluronate (HA), administered once daily (FISER B105). Methods: Fourty patients affected with ocular hypertension or primary open angle glaucoma, well controlled (IOP< 18 mmHg) by monotherapy with beta-blockers, were included in a perspective, double-blind, controlled, randomized clinical trial. After a wash-out period of 4 weeks, baseline IOP was determined, then the patients were divided into two groups: Group A (20 patients, 9 M-11 F, mean age 62±10 years) was treated with FISER B105 in the morning and with vehicle of FISER B105 in the evening; Group B (20 patients, 10 M-10 F, mean age 60±11 years) was treated with timolol 0.5% BID. Measurements of the IOP (before and two hours after morning dosing of the eye drops), brachial artery blood pressure and heart rate, examination of anterior segment were performed at baseline (T0) and at day 7 (T7), day 30 (T30) and day 60 (T60) of treatment. At T0 and T60 patients were required to self-administer a symptoms questionnaire (Glaucoma Symptom Scale). Results: IOP values (mean + SD) measured before (0) and after 2 hours (2h) from morning dose are shown in the table: Both drugs reduced significantly the IOP (p=0.001, ANOVA). No significant differences were registered between the two groups in IOP, anterior segment examination, blood pressure and heart rate at all measurements. As regards the symptoms questionnaire, no difference was seen between the two groups at the baseline visit while at the final visit, the group A patients showed a lower incidence of four out of ten symptoms investigated by means of questionnaire (p<0.01, Chi-square test) (i.e. burning/stinging, dryness, itching, foreign body sensation). Conclusions: Fiser B105 administered once daily reduces the IOP in a comparable way with timolol 0.5% BID. These results could be due to the increased aqueous bioavailability of timolol when formulated in a mucoadhesive, viscoelastic HA vehicle in comparison with water solution. FISER B105 resulted also in a better tolerability.  

Keywords: intraocular pressure • clinical (human) or epidemiologic studies: tretment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×